Published • loading... • Updated
New Pill Could Lower Bad Cholesterol as Louisiana Faces Higher-than-Average Rates
The once-daily tablet lowered LDL cholesterol by 56% to 59% in trials involving 3,207 adults, offering a new option beyond injectables.
- Last week, the FDA approved Merck's Lipfendra, the first oral PCSK9 inhibitor for lowering LDL cholesterol in adults with high cholesterol or heterozygous familial hypercholesterolaemia .
- Lipfendra blocks the PCSK9 protein, enabling the liver to clear LDL cholesterol more effectively; this mechanism was previously available only through injectable therapies from companies like Amgen.
- Clinical trials involving 3,207 adults showed LDL reductions of 56% to 59% after 24 weeks. Dr. Rahul Mehrotra of Artemis Hospitals notes this is "very significant" as it directly reduces cardiovascular risk.
- Patients with high-risk ASCVD or HeFH who require additional help beyond statins may benefit most, particularly those unable or unwilling to use injectable medications.
- While cholesterol-lowering efficacy is encouraging, Dr. Jagadish Hiremath notes that long-term outcome studies are required to determine if these reductions translate into fewer cardiovascular events.
Insights by Ground AI
12 Articles
12 Articles
FDA approves new daily pill to lower bad cholesterol: What you need to know
The FDA has approved Lipfendra, a once-daily oral PCSK9 inhibitor for adults with high LDL cholesterol. The pill offers an alternative to injections for patients who need further LDL reduction beyond statins.
·Noida, India
Read Full Article
FDA approves new, more efficient pill to lower cholesterol
The U.S. Food and Drug Administration on Thursday approved a new daily pill that lowers levels of dangerous cholesterol. The pill is expected to boost compliance rates compared to previously used medications, according to a Thursday news release from the…
Coverage Details
Total News Sources12
Leaning Left2Leaning Right1Center5Last UpdatedBias Distribution63% Center
Bias Distribution
- 63% of the sources are Center
63% Center
L 25%
C 63%
12%
Factuality
To view factuality data please Upgrade to Premium
